SYAB Stock Overview
Provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
SYNLAB AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €11.14 |
52 Week High | €11.08 |
52 Week Low | €10.86 |
Beta | 0.89 |
11 Month Change | 1.64% |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 1.09% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
SYAB | DE Healthcare | DE Market | |
---|---|---|---|
7D | 2.0% | 1.7% | 0.9% |
1Y | n/a | -1.2% | 4.9% |
Return vs Industry: Insufficient data to determine how SYAB performed against the German Healthcare industry.
Return vs Market: Insufficient data to determine how SYAB performed against the German Market.
Price Volatility
SYAB volatility | |
---|---|
SYAB Average Weekly Movement | n/a |
Healthcare Industry Average Movement | 3.8% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 11.1% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: SYAB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SYAB's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 27,000 | Mathieu Floreani | www.synlab.com |
SYNLAB AG provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe. The company offers medical and veterinary diagnostics services. SYNLAB AG was founded in 1998 and is headquartered in Munich, Germany.
SYNLAB AG Fundamentals Summary
SYAB fundamental statistics | |
---|---|
Market cap | €2.43b |
Earnings (TTM) | €89.35m |
Revenue (TTM) | €2.62b |
27.2x
P/E Ratio0.9x
P/S RatioIs SYAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SYAB income statement (TTM) | |
---|---|
Revenue | €2.62b |
Cost of Revenue | €604.92m |
Gross Profit | €2.01b |
Other Expenses | €1.92b |
Earnings | €89.35m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Nov 07, 2024
Earnings per share (EPS) | 0.41 |
Gross Margin | 76.87% |
Net Profit Margin | 3.42% |
Debt/Equity Ratio | 39.0% |
How did SYAB perform over the long term?
See historical performance and comparison